Mohammad Nawaz, MD
Cardiovascular Disease · Frisco, TXNPI 1669687299
Payments from drug & device makers
Across 49 payments — averaging $61.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$994
- Amgen$511
- Merck$439
- AstraZeneca$214
- Medtronic$172
- Reflow Medical Inc$170
- plus $524 from 10 others
What the payments were for
- Travel & lodging$81527%
- Food & beverage$2,17072%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 7 | $994 |
| Amgen | 9 | $511 |
| Merck | 14 | $439 |
| AstraZeneca | 2 | $214 |
| Medtronic | 1 | $172 |
| Reflow Medical Inc | 5 | $170 |
| Impulse Dynamics (USA) Inc. | 1 | $144 |
| Sanofi-aventis U.S. LLC | 2 | $126 |
| Sanofi | 1 | $122 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Astellas Pharma US Inc | 1 | $22 |
| Philips North America LLC | 1 | $21 |
| Globus Medical | 1 | $17 |
| Veryan Medical Incorporated | 1 | $16 |
| Nevro Corp. | 1 | $13 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnilink Elite vascular stent system$807
- Repatha$371
- OPTIMIZER$288
- ONYX FRONTIER$172
- VERQUVO$125
- DUPIXENT$122
- FARXIGA$120
- PRALUENT$119
How this compares
$3,024 in reported general payments places this provider in the 45th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $16,099 |
| EntrestoSacubitril/Valsartan | 15 | $16,008 |
| Repatha SyringeEvolocumab | 14 | $7,709 |
| Nebivolol Hcl | 19 | $1,299 |
| Rosuvastatin Calcium | 49 | $1,052 |
| ClopidogrelClopidogrel Bisulfate | 112 | $997 |
| Metoprolol Succinate | 30 | $663 |
| Atorvastatin Calcium | 41 | $622 |
| Losartan Potassium | 40 | $477 |
| Carvedilol | 50 | $427 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 19 | $313 |
| Spironolactone | 23 | $281 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 13 | $210 |
| Amlodipine Besylate | 37 | $185 |
| Lisinopril | 15 | $135 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Frisco
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.